Radiation Therapy or Temozolomide in Treating Patients With Gliomas
Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study
Sponsor: British Medical Research Council
Listed as NCT00182819, this PHASE3 trial focuses on Brain and Central Nervous System Tumors and remains completed. Sponsored by British Medical Research Council, it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jul 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- British Medical Research Council
- European Organisation for Research and Treatment of Cancer - EORTC
- NCIC Clinical Trials Group
- Trans Tasman Radiation Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amsterdam, Netherlands, Badalona - (Barcelona), Spain, Barcelona, Spain, Bebington, Wirral, United Kingdom, Bellinzona, Switzerland, Bologna, Italy, Bordeaux, France, Brisbane, Australia, Bristol, United Kingdom, Brussels, Belgium and 69 more location s